The Mayo Clinic Cancer Center (MCCC) is fully committed to addressing cancer-related determinants and outcomes through its leadership in basic, translational, and population sciences cancer research. The MCCC has re-defined its catchment areas (CAs) at its 3 sites as the counties where Mayo Clinic has a physical presence (clinic/hospital), plus the geographically contiguous counties that these sites serve. The Community Outreach and Engagement (COE) effort is led by Dr. Carmen Radecki Breitkopf, Associate Director for Cancer Disparities and Community Outreach.
COE Specific Aims i nclude: (1) Assess needs through ongoing community outreach and engagement efforts to prioritize initiatives and research in our catchment areas. We monitor the cancer burden, needs, opportunities, and challenges in each catchment area; assess the impact of the MCCC's and institutional investment in outreach and cancer disparities infrastructure; and extend meaningful partnerships with our community-based affiliations and engage our Community Advisory Boards to help set priorities. (2) Implement and facilitate evidence-based programs and research to reduce cancer burden in our catchment areas (CAs). We identify COE-inspired opportunities for cancer research by MCCC investigators, especially where needs for data to support impactful change and implementation can be encouraged; enhance communications strategies to increase awareness of CAs among MCCC investigators (messaging, MCCC newsletters, seminars); promote use of COE research expertise and infrastructure resources (community outreach workers, study coordinators, partnership opportunities) to increase diversity of participants in research; and promote cancer research strategies that address barriers and disparities in the rural populations of our CAs. (3) Evaluate the impact of MCCC and monitor needs for research and expertise in the MCCC CAs and beyond. We contribute leadership and participation in our state cancer plans and facilitate academic and community collaborations to effect policy change; and foster MCCC relationships with Native American tribes across the US. Through COE, MCCC is committed to decreasing cancer incidence and mortality in its catchment areas. Our research in cancer risk assessment, prevention, screening, treatment, and survivorship enhances activities that address community needs. Through our research and engagement in our catchment areas we have an impact at all levels, from the individual to providers to policy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113621
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications